Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124)(NSE:DRREDDY) (NYSE:RDY) on Wednesday announced the availability of Bortezomib for Injection 3.5 mg/vial for intravenous use only in the US cancer market.

The company added that the Bortezomib for Injection 3.5 mg/vial has been approved by the US Food and Drug Administration (USFDA) via a 505(b)(2) new drug application (NDA) pathway.

In addition, the US FDA has approved the company's Bortezomib for Injection 3.5 mg/vial for the treatment of adult patients with multiple myeloma as well as for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

Dr Reddy's Laboratories stated that it is committed to providing affordable and innovative medicines for healthier lives. It operates through three businesses: Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products.